期刊文献+

青钱柳提取物对HepG2 2.2.15细胞HBsAg和HBeAg表达的影响 被引量:5

Inhibiting effect of Cyclocarya paliurus extracts on HBsAg and HBeAg expression of the HepG2 2.2.15 cells
下载PDF
导出
摘要 目的研究青钱柳提取物体外抗乙肝病毒作用。方法青钱柳用75%乙醇提取后按溶剂极性萃取,获得的三氯甲烷部位经柱层析得到Fr.2组分。体外培养HepG2 2.2.15细胞,MTT法检测青钱柳提取物Fr.2组分对HepG22.2.15细胞的细胞毒作用,用ELISA法检测HepG2 2.2.15细胞培养液中HBsAg和HBeAg的表达。结果青钱柳提取物Fr.2组分对HepG2 2.2.15细胞无明显的细胞毒作用。与对照组比较,Fr.2组分对HBsAg和HBeAg的表达均有显著性抑制作用(P<0.01或0.05)。结论青钱柳提取物体外具有较强的抗乙肝病毒作用。 AIM To explore the anti-hepatitis B virus(HBV) effects of the Cyclocarya paliurus extract by using the HepG2 2.2.15 cell lines.METHODS The Cyclocarya paliurus was macerated with 75% ethanol and fractionated through solvent-solvent partitioning.The Fr.2 fraction was obtained from chloroform extract by column chromatography.HepG2 2.2.15 cells were cultured for in vitro anti-hepatitis B virus test.MTT chromatometry was used to analyse the cytotoxicity of Fr.2 fraction to HepG2 2.2.15 cell.ELISA was used to detect HBsAg and HBeAg expression in the HepG2 2.2.15 cell lines.RESULTS The Fr.2 fraction had obvious inhibitory effects on the expressions of HBsAg and HBeAg in HepG2 2.2.15 cell lines without cytotoxicity,as compared with those of the control group(P 0.01 or 0.05).CONCLUSION The Cyclocarya paliurus extracts have strong anti-HBV action in vitro.
出处 《中成药》 CAS CSCD 北大核心 2012年第7期1220-1224,共5页 Chinese Traditional Patent Medicine
基金 广西科学与技术开发计划项目(桂科攻0424008-1L)
关键词 青钱柳 HEPG2 2.2.15细胞 HBSAG HBEAG Cyclocarya paliurus HepG2 2.2.15 cells HBsAg HBeAg
  • 相关文献

参考文献9

二级参考文献62

共引文献322

同被引文献54

  • 1张丽欣,李垚.植物黄酮抗病毒作用的研究进展[J].黑龙江科学,2010,1(3):33-37. 被引量:2
  • 2乔园园,郭盛.分子模拟软件MOE及其在药物发现中的应用示例[J].计算机与应用化学,2005,22(2):157-160. 被引量:13
  • 3刘士敬.抗乙肝病毒治疗药物的研究进展[J].中国社区医师,2006,22(15):19-20. 被引量:1
  • 4周艳萌,吴中明,向晓波.土贝母皂苷体外抗乙型肝炎病毒的药效研究[J].时珍国医国药,2006,17(11):2134-2136. 被引量:12
  • 5吴迪矛,巨勇.胆甾酸缀合物的生物及生理学功能[J].化学进展,2007,19(4):544-556. 被引量:4
  • 6Winnie Yeo,Tung C Chan, Nancy W Y Leung. Hepatitis B virus reactivation in Lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab l-J3. journal of Clinical Oncology, 2009,27 (4) .. 605.
  • 7Millward MJ, Zaleberg J, Bishop JF, et al. Phase It rial of do celaxe land eisplat in inprevious lyunt reated patients with ad- vanced non-small cell lung cancer 1-33. J Clin Oncol, 1997,15 (2) : 750.
  • 8hih-hung HSU, Hui-ling, hui-cheng HSU, et al. ann-lii cheng Doxorubcin activates hepatitis B virus replication in HBV-harbo- ring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy [J]. Anticancer research,2004, 24 : 3035-3040.
  • 9Lalazar G,Rund D,Shouval D. Screening prevention and treat-ment of viral hepatitis B reactivation in patient with haematologi- cal malignancies [J]. Br J Haemtol,2007,136(3) :699-712.
  • 10Zhong S, Yeo W, Schroder C, et al. High hepatit is B virus (HBV)DNA virus load is an important risk factor for HBV reac- tivation in breast cancer patients undergoing cytotoxic chemo- therapy [J]. J Viral Hepat,2004,11(1):55-59.

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部